The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

par Golay, Josée, Taylor, Ronald P.
Publié dans Antibodies (Basel) (2020)

Immunotherapeutic Mechanisms of Anti-CD20 Monoclonal Antibodies

par Taylor, Ronald P., Lindorfer, Margaret A.
Publié 2008

Antigenic Modulation and Rituximab Resistance

par Taylor, Ronald P., Lindorfer, Margaret A.
Publié 2010

Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

par Taylor, Ronald P., Lindorfer, Margaret A.
Publié 2014

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca(2+)

par Taylor, Ronald P., Lindorfer, Margaret A.
Publié dans Antibodies (Basel) (2020)

Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes

par Taylor, Ronald P., Lindorfer, Margaret A., Atkinson, John P.
Publié dans Alzheimers Dement (N Y) (2020)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

par Lindorfer, Margaret A., Wiestner, Adrian, Zent, Clive S., Taylor, Ronald P.
Publié 2012

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

par Wang, Siao-Yi, Racila, Emilian, Taylor, Ronald P., Weiner, George J.
Publié 2008

Complement consumption in children with Plasmodium falciparum malaria

par Nyakoe, Nancy K, Taylor, Ronald P, Makumi, Joseph N, Waitumbi, John N
Publié 2009

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia

par Lindorfer, Margaret A., Cook, Erika M., Reis, Edimara S., Ricklin, Daniel, Risitano, Antonio M., Lambris, John D., Taylor, Ronald P.
Publié dans Clin Immunol (2016)

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

par Aue, Georg, Lindorfer, Margaret A., Beum, Paul V., Pawluczkowycz, Andrew W., Vire, Berengere, Hughes, Thomas, Taylor, Ronald P., Wiestner, Adrian
Publié 2010

Complement C1r serine protease contributes to kidney fibrosis

par Xavier, Sandhya, Sahu, Ranjit K., Bontha, Sai Vineela, Mas, Valeria, Taylor, Ronald P., Megyesi, Judit, Thielens, Nicole M., Portilla, Didier
Publié dans Am J Physiol Renal Physiol (2019)

Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

par Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.
Publié dans Leuk Lymphoma (2012)

A humanised antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors()

par Paixão-Cavalcante, Danielle, Torreira, Eva, Lindorfer, Margaret A., de Cordoba, Santiago Rodriguez, Morgan, B. Paul, Taylor, Ronald P., Llorca, Oscar, Harris, Claire L.
Publié 2014

Human complement receptor type 1–directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis

par Zaitsev, Sergei, Danielyan, Kristina, Murciano, Juan-Carlos, Ganguly, Kumkum, Krasik, Tatiana, Taylor, Ronald P., Pincus, Steven, Jones, Steven, Cines, Douglas B., Muzykantov, Vladimir R.
Publié 2006

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

par Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Publié 2013

Induced Resistance to Ofatumumab Mediated Cell Clearance Mechanisms, Including Complement Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

par Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pettinger, Adam M., Shanafelt, Tait D., Nowakowski, Grzegorz S., Zent, Clive S.
Publié dans J Immunol (2014)

Exhaustion of cytotoxic effector systems may limit mAb-based immunotherapy in cancer patients()

par Beurskens, Frank J., Lindorfer, Margaret A., Farooqui, Mohammed, Beum, Paul V., Engelberts, Patrick, Mackus, Wendy J.M., Parren, Paul W.H.I., Wiestner, Adrian, Taylor, Ronald P.
Publié 2012

C3(H(2)O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh(–/–) Cfd(–/–) mice

par Zhang, Yuzhou, Keenan, Adam, Dai, Dao-Fu, May, Kristofer S., Anderson, Emily E., Lindorfer, Margaret A., Henrich, John B., Pitcher, Gabriella R., Taylor, Ronald P., Smith, Richard J.H.
Publié dans JCI Insight (2020)

Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage

par Walsh, Mary C., Shaffer, Lisa A., Guikema, Benjamin J., Body, Simon C., Shernan, Stanton K., Fox, Amanda A., Collard, Charles D., Fung, Michael, Taylor, Ronald P., Stahl, Gregory L.
Publié 2007